奈帕拉唑 | 156601-79-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 奈帕拉唑
• 英文名称: (9R)-9-[(S)-1H-Benzimidazol-2-ylsulfinyl]-4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
• CAS: 156601-79-5
• 化学式: C₁₈H₁₉N₃O₂S
• 分子量: 341.4
• InChiKey: JWMQOWBYKLZSPY-GYCJOSAFSA-N

物化性质

• 沸点：
  626.4±65.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS<br/>[FR] CONJUGUÉS DE COMPOSÉS HÉTÉROAROMATIQUES CONTENANT DE L'AZOTE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2020254606A1

  公开（公告）日：2020-12-24

  The present invention relates to conjugates of ΤΓ-electron-pair-donating heteroaromatic nitrogen-comprising drugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said conjugates and the use of said conjugates as medicaments.

  本发明涉及ΤΓ-电子对供体杂芳氮含药物及其药用盐的结合物，包括所述结合物的药物组合物以及将所述结合物用作药物的用途。
• PREPARATION AND UTILITY OF SUBSTITUTED ERYTHROMYCIN ANALOGS
  申请人：GANT Thomas G.

  公开号：US20070281894A1

  公开（公告）日：2007-12-06

  The present disclosure is directed to novel macrolide antibiotics of Formula 1 and pharmaceutically acceptable salts and prodrugs thereof; and the chemical syntheses and medical uses of these novel macrolide antibiotics for the treatment and/or management of infections caused by various aerobic and anaerobic gram-positive and gram-negative microorganisms as well as various mycobacteria.

  本公开涉及一种新型大环内酯抗生素的公式1及其药用可接受的盐和前药；以及这些新型大环内酯抗生素的化学合成和医学用途，用于治疗和/或管理由各种需氧和厌氧革兰氏阳性和阴性微生物以及各种分枝杆菌引起的感染。
• Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties
  申请人：Gant G. Thomas

  公开号：US20070082929A1

  公开（公告）日：2007-04-12

  Chemical syntheses and medical uses of novel inhibitors of the gastric H + , K + -ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.

  描述了用于治疗和/或管理十二指肠溃疡、胃灼热、酸反流、其他由胃酸分泌介导的疾病以及牛皮癣的新型胃H+、K+-ATP酶抑制剂的化学合成和医学用途。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。